Corporate Member Update: Pharmacyclics-IMBRUVICA® + RITUXIMAB vs FCR: Data From a Head-to-Head Trial in 1L CLL/SLL
Corporate Member Update: Pharmacyclics-IMBRUVICA® + RITUXIMAB vs FCR: Data From a Head-to-Head Trial in 1L CLL/SLL
Imbruvica
June, 2020
Pharmacyclics has an upcoming unique National Broadcast opportunity happening on Wednesday, June 17th to educate practices on Imbruvica’s new FDA approved label update: IMBRUVICA® + RITUXIMAB vs FCR: Data From a Head-to-Head Trial in 1L CLL/SLL . This format provides a unique opportunity for national participation & interaction. For more information regarding the upcoming event, please click on the flyer below!
